Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Flotetuzumab |
| Synonyms | |
| Therapy Description |
Flotetuzumab (MGD006) is a humanized bispecific antibody that targets both CD123 (IL32A) and CD23, which may lead to anti-leukemic activity (Blood 2017 130(Suppl 1):637, PMID: 32493790, PMID: 32929488). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Flotetuzumab | MGD006|S80880 | CD123 (IL3RA) Antibody 14 | Flotetuzumab (MGD006) is a humanized bispecific antibody that targets both CD123 (IL32A) and CD23, which may lead to anti-leukemic activity (Blood 2017 130(Suppl 1):637, PMID: 32493790, PMID: 32929488). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03739606 | Phase II | Flotetuzumab | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Withdrawn | 0 | |
| NCT04582864 | Phase II | Flotetuzumab | Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | Terminated | USA | 0 |
| NCT02152956 | Phase Ib/II | Flotetuzumab | Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS | Terminated | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | 0 |
| NCT05506956 | Phase I | Flotetuzumab | Post-transplant Flotetuzumab for AML | Completed | USA | 0 |
CKB BOOST